Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New app aims to simplify insulin dosing for diabetes patients

NCT ID NCT06529705

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a mobile app called EkiYou V2 that helps people with diabetes figure out how much insulin to take. 21 adults who use multiple daily insulin injections used the app for 6 weeks. The goal was to see if the app safely improves blood sugar control and makes insulin dosing easier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EkiYou V2 mobile application
What this could lead to
If successful, this app could help people with diabetes better manage their insulin doses and improve blood sugar control without needing extra medication.
What could go wrong
This is a very small, early study with only 21 participants and no comparison group. The results may not apply to everyone, and the app might not work as well in real-world, long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Started

Aug 2024

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : * Be over 18 years old; * Have type 1, type 2, or pancreatogenic diabetes; * Have been treated with multiple daily injections of insulin in a basal/bolus regimen for at least 6 months; * Be using a continuous glucose monitoring device such as Dexcom G6, Dexcom One or Freestyle Libre for at least 2 weeks; * Have a time in the glycemic target range (70-180 mg/dl) of less than 70%; * Require at least 15 units of insulin therapy per day; * Use a rapid-acting insulin compatible with the device, such as Novorapid, Humalog, Apidra, Asparte, Sanofi, Fiasp, or Lyumjev; * Use a long-acting insulin compatible with the device, such as Lantus, Abasaglar, Toujeo, Levemir, or Tresiba; * Be able to read and use a smartphone; * Have no visual impairment requiring a specific font for smartphones; * Have basic knowledge of smartphone use; * Indicate their willingness to follow the protocol and sign a written informed consent Exclusion Criteria: * Ketoacidosis or severe level 3 hypoglycemia requiring third-party intervention within 6 months prior to inclusion; * Treatment with any hypoglycemia-inducing agent other than insulin (including sulfonylureas and SGLT-2 inhibitors); * Daily insulin requirement exceeding 200 U/day; * Suffering from gastroparesis; * Pancreatopathy secondary to chronic alcoholism; * Known medical condition that, in the investigator's opinion, may interfere with the protocol; * Participation in another clinical trial or administration of an unapproved medication within 4 weeks prior to screening; * Not affiliated with a social security system; * Vulnerable subject: minors, or adults under protection as defined by the Public Health Code, pregnant or breastfeeding women, subjects under guardianship or deprived of liberty; * Person under legal protection; * Person participating in another study with an ongoing exclusion period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Montpellier

    Montpellier, France, 34000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.